High efficacy of sofosbuvir/velpatasvir and impact of baseline resistance‐associated substitutions in hepatitis C genotype 3 infection
Alimentary Pharmacology & Therapeutics2018Vol. 47(9), pp. 1288–1295
Citations Over TimeTop 10% of 2018 papers
Johann von Felden, Johannes Vermehren, Patrick Ingiliz, Stefan Mauss, Thomas A. Lutz, Karl‐Georg Simon, H. Busch, Axel Baumgarten, Knud Schewe, D. Hueppe, Christoph Boesecke, JK Rockstroh, Martin Daeumer, Nadine Luebke, Jörg Timm, Julian Schulze zur Wiesch, Christoph Sarrazin, Stefan Christensen
Abstract
Twelve weeks of SOL/VEL±RBV was safe and highly efficient in HCV GT3 across a diverse patient population. Baseline NS5A RASs were rarely observed and presence did not seem to impact SVR, regardless of the use of RBV.
Related Papers
- → Health-related quality of life in children with hepatitis C viral (HCV) infection treated with sofosbuvir and ribavirin(2017)1 cited
- Successful use of generic direct acting antiviral medications to treat hepatitis C-a New Zealand-wide study.(2020)
- → Safety and Efficacy of Ledipasvir/Sofosbuvir on Hepatitis C Eradication in HCV/ HIV Co-infected Patients(2017)
- → Faculty Opinions recommendation of Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options.(2013)